Early during Myelomagenesis Alterations in DNA Methylation That Occur Myeloma Is Characterized by Stage-Specific

Epigenetic changes play important roles in carcinogenesis and influence initial steps in neoplastic transformation by altering genome stability and regulating gene expression. To characterize epigenomic changes during the transformation of normal plasma cells to myeloma, we modified the HpaII tiny fragment enrichment by ligation–mediated PCR assay to work with small numbers of purified primary marrow plasma cells. The nano-HpaII tiny fragment enrichment by ligation–mediated PCR assay was used to analyze the methylome of CD138 + cells from 56 subjects representing premalignant (monoclonal gammopathy of uncertain significance), early, and advanced stages of myeloma, as well as healthy controls. Plasma cells from premalignant and early stages of myeloma were characterized by striking, widespread hypomethylation. Gene-specific hypermethylation was seen to occur in the advanced stages, and cell lines representative of relapsed cases were found to be sensitive to decitabine. Aberrant demethylation in monoclonal gammopathy of uncertain significance occurred primarily in CpG islands, whereas differentially methylated loci in cases of myeloma occurred predominantly outside of CpG islands and affected distinct sets of gene pathways, demonstrating qualitative epigenetic differences between premalignant and malignant stages. Examination of the methylation machinery revealed that the methyltransferase, DNMT3A, was aberrantly hypermethylated and underexpressed, but not mutated in myeloma. DNMT3A underexpression was also associated with adverse overall survival in a large cohort of patients, providing insights into genesis of hypomethylation in myeloma. These results demonstrate widespread, stage-specific epigenetic changes during myelomagenesis and suggest that early demethylation can be a potential contributor to genome instability seen in myeloma. We also identify DNMT3A expression as a novel prognostic biomarker and suggest that relapsed cases can be therapeutically targeted by hypomethylating agents. The Journal of Immunology , 2013, 190: 000–000.

[1]  Robert Brown,et al.  Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling , 2012, Oncogene.

[2]  Nita Ahuja,et al.  Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. , 2012, Cancer cell.

[3]  A. Jankowska,et al.  CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors , 2011, Leukemia.

[4]  W. Wilson,et al.  High-Resolution Sequencing Identifies NOXA1 De-Methylation As a Novel Strategy to Overcome Bortezomib Resistance in Mantle Cell Lymphoma , 2011 .

[5]  K. Nephew,et al.  GPx3 promoter hypermethylation is a frequent event in human cancer and is associated with tumorigenesis and chemotherapy response. , 2011, Cancer letters.

[6]  J. Herman,et al.  Methylation-associated dysregulation of the suppressor of cytokine signaling-3 gene in multiple myeloma , 2011, Epigenetics.

[7]  K. Wagner,et al.  Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Bartoszek,et al.  DNA methylation in cancer development, diagnosis and therapy--multiple opportunities for genotoxic agents to act as methylome disruptors or remediators. , 2011, Mutagenesis.

[9]  O. Abdel-Wahab,et al.  Aberrant Epigenetic and Genetic Marks Are Seen in Myelodysplastic Leukocytes and Reveal Dock4 as a Candidate Pathogenic Gene on Chromosome 7q* , 2011, The Journal of Biological Chemistry.

[10]  J. Licht,et al.  DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.

[11]  Reid F. Thompson,et al.  Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis , 2011, PLoS genetics.

[12]  Trevor J Pugh,et al.  Initial genome sequencing and analysis of multiple myeloma , 2011, Nature.

[13]  Fiona M Ross,et al.  Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. , 2011, Blood.

[14]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[15]  S. Singhal,et al.  DNA methylation alterations in multiple myeloma as a model for epigenetic changes in cancer , 2010, Wiley interdisciplinary reviews. Systems biology and medicine.

[16]  J. Carpten,et al.  DNA methylation analysis determines the high frequency of genic hypomethylation and low frequency of hypermethylation events in plasma cell tumors. , 2010, Cancer research.

[17]  Fabien Campagne,et al.  DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. , 2010, Cancer cell.

[18]  Peter A. Jones,et al.  Rethinking how DNA methylation patterns are maintained , 2009, Nature Reviews Genetics.

[19]  J. Nevins,et al.  Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  H. Asaoku,et al.  Genomic Screening for Genes Silenced by DNA Methylation Revealed an Association between RASD1 Inactivation and Dexamethasone Resistance in Multiple Myeloma , 2009, Clinical Cancer Research.

[21]  B. Barlogie,et al.  Gene expression profiling of plasma cells at myeloma relapse from tandem transplantation trial Total Therapy 2 predicts subsequent survival. , 2009, Blood.

[22]  Reid F. Thompson,et al.  High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers , 2009, Nucleic acids research.

[23]  A. Feinberg,et al.  Genome-wide methylation analysis of human colon cancer reveals similar hypo- and hypermethylation at conserved tissue-specific CpG island shores , 2008, Nature Genetics.

[24]  M. Bitzer,et al.  Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS. , 2008, Blood.

[25]  Kenny Q. Ye,et al.  Meta-Analysis of Microarray Studies Reveals a Novel Hematopoietic Progenitor Cell Signature and Demonstrates Feasibility of Inter-Platform Data Integration , 2008, PloS one.

[26]  D. Owen,et al.  SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response , 2008, British Journal of Cancer.

[27]  Quan Chen,et al.  An analytical pipeline for genomic representations used for cytosine methylation studies , 2008, Bioinform..

[28]  David R Williams,et al.  Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis. , 2006, Blood.

[29]  John Crowley,et al.  The molecular classification of multiple myeloma. , 2006, Blood.

[30]  Kenny Q. Ye,et al.  Comparative isoschizomer profiling of cytosine methylation: the HELP assay. , 2006, Genome research.

[31]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Bart Barlogie,et al.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.

[33]  Johanna S. Hardin,et al.  Evaluation of Multiple Models to Distinguish Closely Related Forms of Disease Using DNA Microarray Data: an Application to Multiple Myeloma , 2004, Statistical applications in genetics and molecular biology.

[34]  M. Esteller.  Cancer epigenetics: DNA methylation and chromatin alterations in human cancer. , 2003, Advances in experimental medicine and biology.

[35]  M. Ehrlich,et al.  DNA methylation in cancer: too much, but also too little , 2002, Oncogene.

[36]  M. Kubota,et al.  Cancer chemotherapy and somatic cell mutation. , 2000, Mutation research.

[37]  L. Glória,et al.  Global DNA hypomethylation occurs in the early stages of intestinal type gastric carcinoma. , 1996, Gut.